STING1 and triple-negative breast carcinoma: The cGAS-STING pathway has been recognized as an activator of the antitumor immune response [29], and in triple-negative breast cancer, the efficacy of olaparib depends on the activation of the cGAS-STING pathway, which recruits CD8+ T cells into the tumor microenvironment, thereby triggering an antitumor immune response [30].